San Diego, CA--January 21, 2011--Mentor Capital, Inc. (Pink Sheets: MNTR) announced that it has entered into discussions with a private biotechnology company regarding a possible strategic relationship, including a possible merger. Consistent with Mentor’s strategic focus of investing in leading edge cancer immunotherapy companies, the biotechnology company is developing a targeted cancer immunotherapy, and is preparing to enter into late stage clinical trials.

“The combination of Mentor’s financial resources with the Company’s novel and exciting late stage immunotherapy platform is the strategic focus that Mentor Capital is looking to achieve.“ commented Chet Billingsley, CEO and Chairman of Mentor Capital.

Mentor Capital, Inc. invests in leading edge cancer companies. Cutting edge science, unmet medical needs, and paradigm changing treatments are key attributes of companies Mentor seeks for investment. Upon closing of any strategic transaction, non-cancer legacy assets held by Mentor are intended to be monetized and directed toward additional cancer related investment.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.

Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top